Back to Search

OMER

Omeros Corporation
Data: 2026-10-02
$18.61
Price
0.76%
Change
$21.24
52W High
$4.06
52W Low
Full AI Analysis Buy/Sell Forecast Trendline Why Moving Charts Options
Analyzing positioning… Options positioning — based on yesterday's biggest open-interest changes See the chart Institutional flows
Track record
signal day → next-day price move
Quick Stats
Oct 02, 2026

54.2

AI Score

HOLD

0.63

Volume Ratio

Nov 12, 2026

Next Earnings

13

+ve Days (30d)

17

-ve Days (30d)

OMER Price vs Max Options Open Interest

How to read this: the line is the stock price; the bars show where the most option open interest sits each day. Strikes with heavy open interest often act as magnets or barriers for price ("max pain" zones). Scroll right for the most recent days.

OMER Max Change In Options Open Interest

How to read this: each bar is the option contract whose open interest changed the most yesterday. Green bars = new positions being opened (conviction building at that strike); red bars = positions being closed. Call builds above the current price suggest upside bets; put builds below it suggest hedging or downside bets.

OMER Options - Sort by Max open Interest (near term)

3rd October 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

OMER Daily Out of Money Options - Sort by Max open Interest (near term)

3rd October 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

OMER Daily In the Money Options - Sort by Max open Interest (near term)

3rd October 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

OMER Most Active Options by Volume(near term)

3rd October 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI		 Ask PC Delta Vega Volatility % change Track
OMER Technical Chart Pro Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select an indicator above — it will be added as a pane under the price chart with aligned dates.

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

OMER Stock Summary

Last updated Oct 02, 2026

OMER is currently trading at $18.61, positioned above its 200-day moving average of $13.0, indicating a long-term uptrend. The stock has a 52-week range of $4.055 to $21.2399.

Technical Analysis: The 50-day moving average stands at $16.94, which is below the current price, signaling bullish near-term momentum. The RSI (Relative Strength Index) reads 51.191, suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.057, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates OMER at 54.2/100 with a HOLD recommendation.

OMER (Omeros Corporation) Indicators

Last updated Oct 02, 2026

Indicator Value
RSI(14) 51.191
CMF (20) -0.057
ROC (10) 4.141
ADX (14) 27.04
Indicator Value
MACD (12,26,9) 0.555
AROONOSC (14) 35.714
WILLAMS %R (14) -55.485
MFI (14) 50.489

OMER Candlestick Patterns

Validated patterns fired in the last 10 sessions. Hit rate = how often price moved in the signal's direction within 5 trading days (backtest: 2.7M signals, 3,500 liquid stocks, Feb 2025–Sep 2026). Baseline: a random stock closes higher 5 days later 53% of the time. Click a row to see the candle on the chart.

Date Pattern Signal 5-Day Hit Rate Edge vs Baseline Sample
Sep 28 Inverted Hammer Bullish 56.4% +3.4 pts 19834

These are statistical tilts, not standalone trade setups. Only patterns with a measured edge are shown — roughly 50 of 60 textbook patterns showed no edge and are hidden.

Omeros Corporation is above both the 50 Day and 200 Day SMA which is considered Bullish.

OMER Moving Averages Analysis

Omeros Corporation has been above 50 day sma 1 times in last 30 days. Last time it was above 50 day sma was on Oct 02, 2026

Omeros Corporation has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Oct 02, 2026

OMER (Omeros Corporation) Simple Moving Averages

Moving Averages are last updated Oct 02, 2026

Days MA
10 19.53
20 18.9
30 18.91
50 16.94
100 13.74
200 13.0

OMER Fundamental Analysis

P/E (Forward) 87.7193
P/E (Trailing) 11.1939
Market Cap ($) 1.3 billion
Earnings/Share ($) 1.65
Net Profit Margin (%) 3.2488
Dividend/Share ($) --
EPS Estimate Current Year ($) 0.69
EPS Estimate Next Year ($) 1.23
WallStreet Target Price ($) 27.50
Most Recent Quarter

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.